

# NANEMIAR

**Nanomedicine Approach to Normalize  
Erythrocyte Maturation in Congenital  
Anemia by messenger RNA**

**PROJECT INFORMATION SHEET**

## PROJECT FACTS

### Duration

01/10/2023 to 30/09/2026 (36 months)

### Programme

HORIZON Europe - The European Union's Horizon Europe Research and Innovation Programme 2021-2027

### Type of Action

HORIZON Research and Innovation Action (RIA)

### Grant Agreement

101080156

### Project partners

1. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS) - Spain (**Coordinator**)
  - Servicio Murciano de Salud (Affiliated Entity to FFIS) - Spain
2. Mercurna BV (Mercurna BV) - The Netherlands
3. Centre National de la Recherche Scientifique (CNRS) - France

### Max. grant amount

2.682.897,50€


### Keywords

Biochemistry and molecular biology, mRNA, lipid nanoparticles, targeted delivery, erythrocytosis, congenital anemia

## PROJECT SUMMARY

Messenger RNA (mRNA) is a versatile tool known for its rapid development, high effectiveness, and low risk. In the NANEMIAR project, we will harness the advantages of mRNA to develop a treatment for congenital anemia.

### Ambition



Development of an mRNA-based drug candidate for treatment of congenital anemias

### Specific objectives



Development of targeted mRNA therapeutic


Pharmaceutical application of mRNA therapeutic



Pre-clinical potential of novel therapeutic


Combining expertise from academic, clinical and industry partners in Spain, France and The Netherlands, we aim to generate an innovative treatment option for congenital anemia, and advance knowledge in targeted therapeutics.

### Outcomes of the call



A nanomedicine base-system for next-generation gene therapies

Proof-of-concept for a safe treatment option for b-thalassemia




### Expected impact



"Health burden of diseases in the EU and worldwide is reduced through effective disease management"

Aligning with The Horizon Europe Strategic Plan for improved therapies and rare diseases.





# NANEMIAR



nanemiar.eu



linkedin.com/showcase/nanemiar/



@nanemiar



@nanemiar



## Funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme 2021- 2027 under the Grant Agreement No 101080156

### PARTNERS:



Fundación para la Formación  
e Investigación Sanitarias  
de la Región de Murcia

IMIB

Instituto Murciano de  
Investigación Biosanitaria  
Pascual Parrilla



ALHETA supports and  
appreciates these  
research efforts.



Spanish Association for the Fight against  
Hemoglobinopathies and Thalassemias